The Block Firm is pleased to share that the U.S. District Court for the District of New Jersey has granted final approval of the nationwide class action settlement in The Block Firm’s case against Breckenridge Pharmaceutical, Inc., marking a successful resolution for consumers who purchased carcinogen-contaminated duloxetine (generic Cymbalta) produced by Breckenridge Pharmaceuticals.
This approval follows the Court’s earlier preliminary approval of the settlement and represents the final step in ensuring relief for affected consumers. In addition, the company agreed to an ongoing injunction to provide relief to consumers in the future.
A Win for Consumers
This case was brought on behalf of patients who alleged that certain Breckenridge duloxetine products were contaminated with carcinogens known as nitrosamines. This result ensures that consumers’ concerns were heard and addressed through the legal process — a significant step toward greater transparency and fairness in the marketplace.
Our Firm’s Role
The Block Firm is proud to have represented the plaintiffs and to have helped secure this important result. From the beginning, our goal has been to advocate for consumers and to ensure they are treated fairly by the companies they trust and depend upon to supply safe medication. The Court’s final approval affirms the hard work and collaboration that made this resolution possible.
What’s Next
The Block Firm is prosecuting additional class actions against drug companies that cut corners and sell unsafe drugs. Read more about our work here.
